Financial Data and Key Metrics Changes - First quarter revenue increased by 44% year-over-year, reaching $809.5 million, with organic growth contributing 3.5% and acquisitive growth contributing 40.6% [14] - Adjusted EBITDA rose by 63% compared to the previous year, totaling $112.2 million, with an adjusted EBITDA margin of 13.9%, the highest first quarter margin in company history [5][15] - Net income was reported at $17.2 million, while adjusted net income was $26.4 million, translating to an earnings per diluted share of $0.47 [15] Business Line Data and Key Metrics Changes - The company has a project backlog of $3.09 billion, indicating strong demand across its markets [5][18] - The commercial sector is experiencing steady project bidding, supported by population migration to the Sun Belt and reshoring trends [6][8] - The public sector is expected to see a 10%-15% increase in total federal, state, and local contract awards for FY 2026 compared to FY 2025 [8][54] Market Data and Key Metrics Changes - The company operates across eight states and over 110 local markets, with approximately 1,000 commercial sector projects planned for the year [7] - The federal and state governments are continuing to invest in infrastructure, which is crucial for the growing economies in the Sun Belt [8][9] Company Strategy and Development Direction - The company aims to double its size to over $6 billion in revenue by 2030, targeting an EBITDA margin growth to approximately 17% [12][13] - Recent acquisitions, including GMJ Paving Company, are part of a strategy to strengthen market position and expand geographic footprint [10][11] - The company is focused on both organic growth and strategic acquisitions to enhance shareholder value [12][81] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for infrastructure projects and the positive impact of recent acquisitions on future growth [9][10] - The company anticipates a busy work season supported by a record backlog and favorable market conditions [13][18] - Management remains optimistic about the reauthorization of the Surface Transportation Program, expecting increased funding for infrastructure projects [9][82] Other Important Information - Cash flow from operations was $82.6 million in Q1, up from $40.7 million in Q1 of the previous year, with expectations to convert 75%-85% of EBITDA to cash flow from operations in FY 2026 [16][17] - The company is on track to reduce its debt to trailing twelve-month EBITDA ratio to approximately 2.5 times by late 2026 [16][80] Q&A Session Summary Question: Can you provide more details on the acquisition pipeline? - Management indicated a robust pipeline with a mix of platform deals and tuck-ins, emphasizing strategic fit and cultural alignment in acquisitions [24][25] Question: Can you elaborate on the organic growth expectations? - Management confirmed a target of 7%-8% organic growth for the fiscal year, despite a lower growth rate in Q1 due to project delays and competitive dynamics [34][35] Question: What is the outlook for public sector bidding? - Management expects public sector contract awards to increase by 10%-15%, with steady demand in the commercial market as well [50][54] Question: How is the integration of recent acquisitions progressing? - Management highlighted successful integration efforts, particularly in Houston, which have created organic growth opportunities [37][38] Question: What is the expected impact of weather on the second quarter? - Management stated that while weather can vary, they do not foresee significant negative impacts on the second quarter's performance [44][49]

Core Insights - Boston Scientific achieved over $20 billion in sales for 2025, marking a mid-teens growth for the second consecutive year, driven by innovation and execution across business units [6][30] - The company reported a Q4 operational sales growth of 14% and organic sales growth of 13%, exceeding guidance [6][29] - Full year 2025 adjusted EPS grew 22% to $3.06, surpassing guidance, with operational sales growth of 19% and organic sales growth of 16% [7][30] Financial Performance - Q4 consolidated revenue reached $5.286 billion, representing a 15.9% reported growth, with operational revenue growth of 14.3% [29] - Full year 2025 consolidated revenue was $20.74 billion, a 19.9% increase, with operational revenue growth of 19.2% [30] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [31] Business Unit Highlights - The U.S. market saw a 17% growth in Q4 and 26% for the full year, particularly strong in EP, WATCHMAN, and ICTx [8] - The Cardiovascular segment delivered 16% operational growth in Q4 and 22% operational growth for the full year [14] - WATCHMAN business grew 29% in Q4, with strong adoption of concomitant procedures [22] Regional Performance - Europe, Middle East, and Africa (EMEA) grew 5% in Q4 and 3% for the full year, with high single-digit growth expected excluding the impact of product discontinuation [9] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, driven by strong performance in Japan and China [10][11] Future Outlook - For Q1 2026, the company expects organic growth of 8.5% to 10% and for the full year, guidance is set at 10% to 11% [8][36] - Adjusted EPS for 2026 is projected to be between $3.43 and $3.49, indicating a growth of 12% to 14% [38] - The company anticipates continued momentum in EP and WATCHMAN, with expectations for the market to grow approximately 15% in 2026 [26][72] Strategic Acquisitions - Boston Scientific announced agreements to acquire Penumbra and Valencia Technologies, expected to close in 2026, enhancing its portfolio in high-growth segments [15][35] - The acquisition of Nalu Medical has been completed, complementing the neuromodulation pain franchise [35]

Core Insights - Techne (TECH) reported revenue of $295.88 million for the quarter ended December 2025, reflecting a slight decline of 0.4% year-over-year, while EPS increased to $0.46 from $0.42 in the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of $292.03 million by 1.32%, and the EPS surpassed the consensus estimate of $0.43 by 8.24% [1] Financial Performance - Organic Growth in Diagnostics and Spatial Biology was reported at 3%, slightly below the average estimate of 3.9% from two analysts [4] - Organic Growth in Protein Sciences showed a decline of 1%, outperforming the estimated decline of 2.2% [4] - Net Sales for Diagnostics and Spatial Biology reached $81.18 million, close to the average estimate of $81.4 million from three analysts [4] - Net Sales for Protein Sciences amounted to $215.08 million, exceeding the average estimate of $207.1 million, representing a year-over-year increase of 1.7% [4] - Intersegment revenue reported a loss of $0.39 million, better than the average estimate of a loss of $0.45 million, but showed a significant year-over-year decline of 23.2% [4] Market Performance - Over the past month, Techne's shares returned -1%, contrasting with the Zacks S&P 500 composite's increase of 0.9% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Financial Data and Key Metrics Changes - In Q4 2025, net sales were approximately $1.5 billion, a 4% increase from the prior year, primarily driven by higher raw material costs and favorable foreign currency translation [17] - Adjusted EBIT for the quarter was $150.6 million, relatively flat compared to the prior year, with adjusted EPS of $0.67, a decrease of $0.18 due to higher interest expense and tax rate [18] - Adjusted EBIT and EBITDA margins expanded by 150 basis points, positioning the company for accelerated growth in the coming years [12] Business Line Data and Key Metrics Changes - The Dispensing and Specialty Closures segment saw a 1% increase in sales, with higher volumes in fragrance and beauty products offset by destocking in personal care and home care markets [19] - Metal Containers segment sales increased by 11%, driven by a 4% growth in volumes, particularly in pet food products [20] - Custom Containers experienced an 8% decrease in sales due to lower margin business exit, but volumes increased by 1% when excluding these [21] Market Data and Key Metrics Changes - The company anticipates organic volume growth in Dispensing and Specialty Closures to be in the low to mid-single digits for 2026, with metal containers expected to grow by a low single-digit percentage [13] - The pet food market continues to drive growth, representing more than half of the metal containers segment volume [23] Company Strategy and Development Direction - The company successfully integrated the Weener acquisition, achieving full run rate synergies and positioning for organic growth exceeding peers [9] - Strategic initiatives are focused on operational excellence, market-leading innovation, and customer partnerships to drive future growth [15] - The company is optimistic about growth opportunities both organically and inorganically as it enters 2026 [12] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a challenging year due to evolving consumer spending trends, but the company adapted and strengthened processes for future agility [10] - The outlook for 2026 includes expectations for significant value creation for shareholders, with a focus on meeting unique customer needs [15] - Management has taken a conservative approach to guidance, considering broader market conditions and potential risks [62] Other Important Information - The company returned approximately $160 million in capital to shareholders and returned to its target leverage range following the Weener acquisition [8] - The company is focused on sustainability initiatives and cost reduction programs to enhance operational efficiency [62] Q&A Session Summary Question: Details on first quarter outlook for Dispensing and Specialty Closures - Management indicated low- to mid-single-digit volumes for the segment, with challenges from low-cost inventory impacting EBIT [29] Question: Changes in order patterns and operations in Dispensing and Specialty Closures - Management acknowledged that the business has evolved significantly, requiring a broader view of macro influences on customer demand [32] Question: Key volume and margin considerations at the low end of guidance - Management highlighted broader market conditions as a potential factor influencing demand and margins [36] Question: Performance of hot fill beverage and destocking impacts - Management confirmed that destocking activity is complete in the Dispensing and Specialty Closures segment, with expectations for stable volumes [40] Question: Growth opportunities in healthcare and pharma - Management expressed confidence in doubling the size of the healthcare business over the next few years, driven by strong market demand [66]

Financial Data and Key Metrics Changes - In Q4 2025, net sales were approximately $1.5 billion, a 4% increase from the prior year, primarily driven by higher raw material costs and favorable foreign currency translation [15][16] - Adjusted EBIT for the quarter was $150.6 million, relatively flat compared to the prior year, while adjusted EPS decreased by $0.18 to $0.67 due to higher interest expenses and tax rates [16] - Adjusted EBIT and EBITDA margins expanded by 150 basis points, positioning the company for accelerated growth in the coming years [11] Business Line Data and Key Metrics Changes - The Dispensing and Specialty Closures segment saw a 1% increase in sales, with higher volumes in fragrance and beauty products offset by destocking in personal and home care markets [16][17] - Metal Containers segment sales increased by 11%, driven by a 4% growth in volumes, particularly in pet food products [18][19] - Custom Containers experienced an 8% decrease in sales due to exiting lower-margin business, but volumes increased by 1% when excluding these [19] Market Data and Key Metrics Changes - The company anticipates organic volume growth in Dispensing and Specialty Closures to be in the low to mid-single digits for 2026, with metal containers expected to grow by a low single-digit percentage [12][21] - The pet food market continues to drive growth, representing more than half of the metal containers segment volume [21] Company Strategy and Development Direction - The company successfully integrated the Weener acquisition, achieving full run rate synergies and positioning for organic growth exceeding peers [6][8] - Strategic initiatives focus on operational excellence, market-leading innovation, and customer partnerships to drive future growth [7][12] - The company is optimistic about growth opportunities in both organic and inorganic avenues, particularly in healthcare and pharmaceuticals [11][62] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a challenging year due to evolving consumer spending trends, but the company adapted and strengthened processes for future agility [6][9] - The outlook for 2026 includes expectations for significant value creation for shareholders, with a focus on meeting customer needs and navigating market volatility [12][60] - Management has taken a conservative approach to guidance, incorporating broader market risks into their forecasts [60] Other Important Information - The company returned approximately $160 million in capital to shareholders and returned to its target leverage range post-acquisition [6] - The company expects free cash flow of approximately $450 million for 2026, with capital expenditures of about $310 million to support future growth [22] Q&A Session Summary Question: Details on first quarter outlook for Dispensing and Specialty Closures - Management indicated low- to mid-single-digit volume expectations, with challenges from low-cost inventory impacting EBIT [27][30] Question: Changes in order patterns and operations in Dispensing and Specialty Closures - Management acknowledged that the business has evolved, requiring a broader view of macro influences affecting customer demand [30][31] Question: Volume and margin considerations at the low end of guidance - Management highlighted broader market conditions as a potential factor influencing demand and margins [33] Question: Performance of hot fill beverage and destocking impacts - Management confirmed that destocking activity is complete in the Dispensing and Specialty Closures segment, with expectations for comparable volumes in 2026 [36][49] Question: Growth opportunities in healthcare and pharma - Management expressed confidence in doubling the size of the healthcare business over the next few years, driven by a strong pipeline and potential acquisitions [62][84]

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [19] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [20] - Adjusted EPS for Q4 was $0.80, growing 15% year-over-year, exceeding guidance [19] - Full year 2025 adjusted EPS was $3.06, reflecting a 22% increase compared to 2024, marking the third consecutive year of 20%+ adjusted EPS growth [20] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [5] - Endoscopy achieved 8% organic growth in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [5] - Neuromodulation grew 10% in Q4 and 8% organically for the full year, with strong performance from the brain franchise [6] - Cardiovascular segment delivered 16% operational growth in Q4 and 22% operational growth for the full year [7] - Watchman business grew 29% in Q4 and strong double-digit growth for the full year, driven by concomitant procedures [13] Market Data and Key Metrics Changes - U.S. market grew 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [3] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [4] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [3] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [4] - Strategic acquisitions, including Penumbra and Valencia Technologies, are aimed at entering high-growth segments and expanding product offerings [24][25] - The company is focused on maintaining a strong pipeline of innovative products and expanding its market share in key areas [52][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 10%-11% organic revenue growth for 2026, with adjusted EPS growth of 12%-14% [27][28] - The company expects to face challenges in the first half of 2026 due to product discontinuations but anticipates a stronger performance in the second half [46] - Management highlighted the importance of ongoing investments in R&D and strategic M&A to drive future growth [63] Other Important Information - The company expects full-year 2026 adjusted gross margin to be in line with 2025, with a slight expansion in operating margin anticipated [21] - Free cash flow for 2025 was $3.659 billion, exceeding expectations, with a target of approximately $4.2 billion for 2026 [24] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management noted that U.S. EP grew 35% in Q4, exceeding internal targets, and Watchman grew 29%, indicating strong market performance despite concerns [34][36] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials on Watchman uptake, with robust growth continuing [41] Question: Expectations for EP growth in 2026 - Management expects EP growth to be around 15%, with confidence in maintaining market leadership despite increased competition [44][51] Question: Diversification of growth drivers - Management emphasized ongoing investments in various business units, including Neuromodulation and Urology, to ensure consistent performance across the portfolio [60][62] Question: Confidence in long-term growth targets - Management reaffirmed confidence in achieving long-term revenue growth targets of 10%+, supported by strategic acquisitions and market leadership [86]

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [18] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [19] - Adjusted EPS for Q4 2025 was $0.80, a 15% increase from 2024, exceeding guidance [18] - Full year 2025 adjusted EPS was $3.06, growing 22% versus 2024, also exceeding guidance [19] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [20] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [4] - Endoscopy achieved organic growth of 8% in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [4] - Neuromodulation grew 10% in Q4 and delivered 8% organic growth for the full year, with strong performance from the brain franchise [5] - Cardiovascular segment delivered 16% growth operationally in Q4 and 22% operationally for the full year [6] - Watchman business grew 29% in Q4 and maintained strong double-digit growth for the full year [12] Market Data and Key Metrics Changes - U.S. operational growth was 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [2] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [3] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [2] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [3] - Strategic acquisitions, including Penumbra and Valencia Technologies, are aimed at entering high-growth markets and expanding product offerings [24][6] - The company is focused on maintaining a strong pipeline of innovative products and expanding its market share in key segments [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 10%-11% organic revenue growth for 2026, with adjusted EPS growth of 12%-14% [27] - The company expects to face challenges in the first half of 2026 due to product removals and market adjustments but anticipates stronger performance in the latter half [25][43] - Management highlighted the importance of ongoing investments in R&D and strategic M&A to drive long-term growth [61] Other Important Information - The company reported free cash flow of $3,659 million for the full year 2025, exceeding expectations [22] - The legal reserve was $242 million as of December 31, with $46 million already funded [24] - The company maintains a strong balance sheet with cash on hand of $1.965 billion and a gross debt leverage ratio of 1.9 times [23] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management reassured that Q4 results exceeded internal targets, with EP growing 35% and Watchman growing 29%, indicating strong market share gains [30][34] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials and emphasized robust uptake of Watchman procedures [36][38] Question: Expectations for EP growth in 2026 - Management expects EP growth to exceed 15%, driven by new product approvals and market expansion [41][42] Question: Diversification of growth drivers - Management highlighted strong performance expected in Neuromod, Urology, and Endoscopy, with ongoing investments to ensure consistent growth across all business units [59][60]

Core Insights - The company reported Q2 FY 2026 results that exceeded expectations, showcasing solid year-over-year growth in backlog, revenue, adjusted EBITDA, and free cash flow [1][4][18] - Key priorities include performance excellence, driving organic growth, expanding margins, and improving free cash flow [1][5][12][14] Financial Performance - Bookings for Q2 were $288 million with a book-to-bill ratio of 1.23, resulting in a record backlog of nearly $1.5 billion, an increase of 8.8% year-over-year [4][10][18] - Revenue for Q2 was $233 million, reflecting a 4.4% increase compared to the previous year, with first-half revenue up 7.1% year-over-year [4][18][19] - Adjusted EBITDA was $30 million, up 36.3% year-over-year, with an adjusted EBITDA margin of 12.9%, an increase of 300 basis points [5][23][12] - Free cash flow for Q2 was $46 million, significantly ahead of expectations, with net working capital reduced by $61 million year-over-year [5][14][24] Operational Highlights - The company accelerated progress on high-priority customer programs, generating approximately $30 million of revenue planned for Q3 [6][19] - Efforts to increase capacity and automate processes are ongoing, including the expansion of manufacturing space in Phoenix, Arizona [7][8][39] - The focus on customer deliveries led to record first-half revenue and the highest first-half point-in-time revenue since FY 2021 [7][18] Strategic Initiatives - The company is focused on expanding margins through backlog margin expansion and operational optimization, with a goal of achieving adjusted EBITDA margins in the low to mid-twenty percent range [12][13] - Continued emphasis on reducing net working capital, which is now at its lowest level since Q1 FY 2022, with net debt also reduced to $257 million [14][24] - The company anticipates that increased defense budgets and domestic priorities will positively impact demand across multiple programs [11][73] Future Outlook - The company maintains its full-year view for FY 2026, expecting low single-digit annual revenue growth, with Q3 revenue anticipated to be down year-over-year [16][18] - Adjusted EBITDA margin is expected to approach the mid-teens for the full year, with Q4 anticipated to have the highest margin of the fiscal year [17][18] - The company remains optimistic about potential tailwinds from increased global defense budgets and domestic initiatives like Golden Dome [18][73]

Financial Data and Key Metrics Changes - Bookings reached $288 million with a book-to-bill ratio of 1.23, resulting in a record backlog of nearly $1.5 billion, an increase of 8.8% year-over-year [7][21] - Revenue for Q2 was $233 million, reflecting a year-over-year increase of 4.4% [21] - Adjusted EBITDA was $30 million, up 36.3% year-over-year, with an adjusted EBITDA margin of 12.9%, an increase of 300 basis points [7][24] - Free cash flow was $46 million, significantly ahead of expectations, with cash on hand totaling $335 million [8][25] Business Line Data and Key Metrics Changes - The company recognized $4 million in net adverse EAC changes, consistent with previous quarters, indicating sound execution on development and production programs [9] - Approximately $30 million of revenue was accelerated from Q3 into Q2, positively impacting adjusted EBITDA by $10 million [9][24] Market Data and Key Metrics Changes - The company experienced solid execution across its broad portfolio, contributing to a record first-half revenue and the highest first-half point-in-time revenue since FY 2021 [9][17] - Bookings included significant awards from both domestic and international customers, reflecting a mix of franchise program extensions and new design wins [11][12] Company Strategy and Development Direction - The company is focused on four priorities: performance excellence, driving organic growth, expanding margins, and improving free cash flow [5][10] - The strategy includes increasing capacity, adding automation, and consolidating subscale sites to drive scalability and efficiency [10] - The company aims for adjusted EBITDA margins in the low-to-mid 20% range and free cash flow conversion of 50% [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the market backdrop and the potential for increased global defense budgets to positively impact demand [19][90] - The company maintains its full-year outlook for FY 2026, expecting low single-digit annual revenue growth, with Q3 revenue anticipated to decline year-over-year [18][19] Other Important Information - The company ended Q2 with net debt of $257 million, the lowest level since Q1 FY 2022, and continues to focus on reducing net working capital [16][25] - Operating expenses decreased year-over-year, driven by efficiency improvements and headcount reductions [23] Q&A Session Questions and Answers Question: How much lower margin backlog is left to convert? - Management indicated that the lower margin backlog will continue to flow through over time, with expectations for most of the impact to be resolved by FY 2027 [33][34] Question: What is the current capacity for the Common Processing Architecture (CPA)? - The company is ramping up production in CPA and is confident in meeting increased demand without significant additional investment [41][42] Question: Why is there no upward revision in guidance despite strong performance? - Management explained that while they have outperformed expectations, they are cautious about future accelerations due to uncertainties in material availability [44][48] Question: What is the impact of unbilled receivables on revenue? - Management acknowledged that unbilled balances are still high and represent a drag on revenue, but they did not quantify the exact impact [73] Question: What is the status of the Golden Dome initiative and international orders? - Management noted ongoing conversations regarding Golden Dome and international opportunities, with potential for significant increases in quantities if these materialize [90]

Financial Data and Key Metrics Changes - Bookings reached $288 million with a book-to-bill ratio of 1.23, resulting in a record backlog of nearly $1.5 billion, an increase of 8.8% year-over-year [7][21] - Revenue for Q2 was $233 million, reflecting a year-over-year increase of 4.4% [21] - Adjusted EBITDA was approximately $30 million, up 36.3% year-over-year, with an adjusted EBITDA margin of 12.9%, an increase of 300 basis points [7][24] - Free cash flow for the quarter was $46 million, down from $82 million in the prior year, primarily due to accelerated cash receipts [25][28] Business Line Data and Key Metrics Changes - The company recognized $4 million of net adverse EAC changes, consistent with previous quarters, indicating sound execution on development and production programs [9] - Approximately $30 million of revenue was generated from accelerated progress on high-priority programs, primarily planned for Q3 [22] Market Data and Key Metrics Changes - The company noted increased defense budgets globally and domestic priorities like Golden Dome as potential drivers for higher demand across multiple programs [13][19] - Customer conversations are progressing regarding significant increases in quantities for various programs, indicating optimism for future demand [90] Company Strategy and Development Direction - The company is focused on four priorities: performance excellence, driving organic growth, expanding margins, and improving free cash flow [5][10] - Efforts to increase capacity and automate processes are ongoing, with a new 50,000 sq ft factory space in Phoenix to support ramp production [10][41] - The company aims for adjusted EBITDA margins in the low-to-mid 20% range and free cash flow conversion of 50% [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the market backdrop and the company's ability to deliver results in line with targeted profiles, despite expecting Q3 revenue to be down year-over-year [18][19] - The company maintains its full-year view for FY 2026, anticipating low single-digit annual revenue growth [18] Other Important Information - The company ended Q2 with $335 million in cash, with net debt reduced to $257 million, the lowest level since Q1 FY 2022 [16][25] - Operating expenses decreased year-over-year, driven by efficiency improvements and headcount reductions [23] Q&A Session Summary Question: How much lower margin backlog is left to convert? - Management indicated that the lower margin backlog will continue to flow through over time, with expectations for improvement as higher margin bookings replace it [33][34] Question: What is the impact of the stop work order on the SCAR program? - Management stated that they do not quantify individual contracts, but the SCAR program is incorporated into their outlook without significant changes [83] Question: What are the potential choke points affecting acceleration? - Management noted that they are actively working with suppliers to address material availability, but cannot guarantee acceleration until materials are confirmed [75][76]